Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: A multicenter, seroepidemiology study

Journal of Infectious Diseases

Volumn 184, Issue 8, 2001, Pages 1022-1028

  Lin, Feng Ying ^a   Philips, Joseph B ^d   Azimi, Parvin H ^e   Weisman, Leonard E ^f   Clark, Penny ^g   Rhoads, George G ^a   Regan, Joan ^a   Concepcion, Nelydia F ^b   Frasch, Carl E ^b   Troendle, James ^a   Brenner, Ruth A ^a   Gray, Barry M ^d,j   Bhushan, Reva ^b,k   Fitzgerald, Geri ^c   Moyer, Patricia ^a   Clemens, John D ^a,l  

^a MSC 7510 ^*

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c WESTAT   (United States)

^d University of Alabama at Birmingham   (United States)

^e Center of Northern California   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j Regional Pediatric Service   (United States)

^k IOWA STATE UNIVERSITY   (United States)

^l International Vaccine Institute   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MATERNAL SERUM; MULTICENTER STUDY; NEWBORN; NEWBORN PERIOD; ONSET AGE; PRIORITY JOURNAL; PROTECTION; SEROCONVERSION; STREPTOCOCCUS AGALACTIAE; UMBILICAL CORD BLOOD;

AGE OF ONSET; ANTIBODIES, BACTERIAL; FEMALE; FETAL BLOOD; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; INFANT, NEWBORN; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 0035887685     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323350     Document Type: Article

References (42)

1. Prevention of perinatal group B streptococcal disease: A public health perspective
2. The sequelae of group B β-hemolytic streptococcal meningitis in early infancy
3. Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection
4. Multiple mouse-protective antibodies directed against group B streptococci
5. Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with the type III-specific polysaccharide
6. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid
7. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
8. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide tetanus toxoid conjugate vaccine
9. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection
10. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence
11. Estimation of the protective level of IgG antibody to the type-specific polysaccharide of group B streptococcus type Ia
12. Early-onset group B streptococcal disease - United States, 1998-1999
13. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis
14. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines
15. Antibiotic susceptibility profile of vertically acquired group B streptococcus
16. Change in antibiotic resistance of group B streptococcus: Impact on intrapartum management
17. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998
18. Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere
19. Neonatal group B streptococcal disease: Screening and prevention
20. Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines
21. Standardization may suffice for licensure of conjugate vaccines
22. Group B streptococcal carriage and disease: A 6-year prospective study
23. Laboratory and field evaluation of selective media for isolation of group B streptococci
24. Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates
25. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent
26. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization
27. Estimation of group B streptococcus type Ia- and V-specific antibodies with different polysaccharide antigen preparations
28. The statistics of anti-typhoid and anti-cholera inoculations and the interpretation of such statistics in general
29. Serum gamma globulin levels in normal, premature, postmature and small-for-date newborn babies
30. Correlation between serum antibody-level against group B streptococci and gestational age in new-borns
31. Transplacental passage of IgG antibody to GBS Ia
32. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines
33. Methods for estimating serological correlates of protection
34. Quantitative measurement of natural and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies
35. Mouse protection assay for group B streptococcus type III
36. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection
37. Immunogenicity of polysaccharides from type III group B streptococcus
38. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus
39. The group B streptococci: From natural history to the specificity of antibodies
40. Prevalence of anti-group B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses
41. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcus type Ia and Ib